A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

103

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision, no safety concerns.

Conditions

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Venetoclax
DRUG: Fulvestrant

Sponsor

Hoffmann-La Roche